Last mentioned: Mar 6, 2026
Strategic Update
COSCIENS announces cessation of funding for German biopharma subsidiaries.
Wuzhou Agreement
Distribution deal signed with Wuzhou Drug International Trading Limited.
FDA Type C Meeting
Regulatory feedback confirms significant hurdles for pediatric expansion.
DETECT Trial Results
Phase 3 trial for pediatric indication yields disappointing results.
COSCIENS Biopharma Inc. has announced a definitive strategic shift by ceasing all funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The decision triggers a structured insolvency process for the units following the failure of a Phase 3 pediatric trial for its flagship diagnostic, Macrilen.
This page surfaces every story mentioning Aeterna Zentaris GmbH across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Aeterna Zentaris GmbH was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |